The nucleoside analog kamuvudine-9 shows protective and therapeutic efficacy in a mouse model of multiple sclerosis.

Kamuvudine-9, an NRTI derivative, prevents neurological deficits and reverses paralysis in a mouse model of multiple sclerosis, showing neuroprotective effects.

• Why it matters: Multiple sclerosis involves inflammasome activation, but current treatments lack targeted therapies that address this pathway; understanding this could improve disease management.
• What they did: Researchers treated experimental autoimmune encephalitis mice with kamuvudine-9, assessing neurological function, myelin preservation, and inflammasome interactions, alongside safety and pharmacokinetics.
• The result: K-9 halted disease progression, restored function, and preserved neural tissue, while epidemiological data linked NRTI use to lower MS incidence and relapse, supporting further therapeutic exploration.